Developing innovative cancer treatments tackling GPCR mediated-immunosuppression
| Discovery | Candidate | Preclinical | Phase I | Partner | |
|---|---|---|---|---|---|
| A2aR/A2bR antagonist (M1069) + |
Phase I
|
||||
| EP4 receptor antagonist (DT-9081) + | Phase I | ||||
| Anti-CCR8 antibody + | Candidate | ||||
| Undisclosed GPCR Target + | Candidate | ||||
| Undisclosed GPCR targets + | Discovery | ||||
We build a high value pipeline focused on GPCRs to rearm immune system against tumors.
A2aR/A2bR antagonist
EP4R antagonist (DT-9081)
Anti-CCR8 antibody
Undisclosed GPCR targets
We are advancing multiple first-in-class and best-in class programs to tackle GPCR-mediated immunosuppression in immune-oncology.
